The authors reported a trend towards an association for BCR with UGT2B17 expression, and no association with UGT2B28.23 However, the commercial UGT2B17 and UGT2B28 antibodies displayed cross-reactivity with other UGT2Bs expressed in prostate tumours based on our specificity screen (Supplementary Fig. 11). Here, BCR is linked to prostate neoplasm.